| 2026 |
| 04/01 | 2,452 | 2,466 | 2,428 | 2,462 | +3.97% | 103,800 | 643億1014万 | +6.17% |
| 03/31 | 2,400 | 2,448 | 2,368 | 2,368 | -2.27% | 133,800 | 618億5476万 | +2.29% |
| 03/30 | 2,353 | 2,437 | 2,324 | 2,423 | -4.08% | 212,400 | 632億9142万 | +4.57% |
| 03/27 | 2,390 | 2,559 | 2,381 | 2,526 | +6.4% | 310,700 | 659億8189万 | +9.16% |
| 03/26 | 2,346 | 2,374 | 2,333 | 2,374 | +0.94% | 83,400 | 620億1149万 | +2.82% |
| 03/25 | 2,288 | 2,355 | 2,287 | 2,352 | +3.34% | 118,200 | 614億3682万 | +2.04% |
| 03/24 | （IR情報）15:30 富士製薬工業とゲデオン・リヒター社、女性医療分野の共同開発プロジェクトに関する合意を締結 |
| 03/24 | 2,276 | 2,307 | 2,255 | 2,276 | +2.25% | 136,900 | 594億5162万 | -1.13% |
| 03/23 | 2,182 | 2,239 | 2,182 | 2,226 | -0.49% | 166,400 | 554億758万 | -3.26% |
| 03/19 | （IR情報）16:30 2026年9月期(第62期)中間配当予想の修正に関するお知らせ |
| 03/19 | （5%ルール）野村證券（2.94%）ノムラインターナショナルピーエルシー(NOMURA IN…（0%）野村アセットマネジメント（1.86%） |
| 03/19 | 2,213 | 2,252 | 2,208 | 2,237 | -1.15% | 169,000 | 556億8139万 | -2.82% |
| 03/18 | 2,218 | 2,272 | 2,218 | 2,263 | +3.76% | 117,400 | 563億2855万 | -1.57% |
| 03/17 | 2,193 | 2,221 | 2,181 | 2,181 | -1.36% | 62,300 | 542億8748万 | -5.01% |
| 03/16 | 2,208 | 2,230 | 2,179 | 2,211 | -0.63% | 82,300 | 550億3422万 | -3.66% |
| 03/13 | 2,190 | 2,257 | 2,190 | 2,225 | -0.31% | 87,500 | 553億8269万 | -2.58% |
| 03/12 | 2,261 | 2,283 | 2,200 | 2,232 | -5.1% | 201,000 | 555億5693万 | -1.72% |
| 03/11 | （IR情報）16:30 第三者割当により発行された第2回新株予約権の行使完了に関するお知らせ |
| 03/11 | 2,335 | 2,383 | 2,307 | 2,352 | +2.93% | 157,200 | 585億4386万 | +4.16% |
| 03/11 | （空売り報告）野村證券 41,791株（0.16%）-0.88%義務消失 |
| 03/10 | （IR情報）15:30 健康経営優良法人2026（大規模法人部門）認定取得のお知らせ |
| 03/10 | 2,302 | 2,360 | 2,284 | 2,285 | +1.47% | 228,400 | 568億7616万 | +2.05% |
| 03/10 | （空売り報告）野村證券 260,691株（1.04%）+0.27% |
| 03/09 | 2,181 | 2,263 | 2,168 | 2,252 | -4.01% | 237,100 | 560億5475万 | +1.26% |
| 03/09 | （空売り報告）野村證券 191,891株（0.77%）再IN |
| 03/06 | 2,314 | 2,346 | 2,290 | 2,346 | -0.76% | 133,100 | 583億9452万 | +6.2% |
| 03/05 | （5%ルール）ノムラインターナショナルピーエルシー(NOMURA IN…（0.06%）野村證券（4.71%）野村アセットマネジメント（1.61%） |
| 03/05 | 2,303 | 2,394 | 2,300 | 2,364 | +4.56% | 194,400 | 588億4256万 | +7.95% |
| 03/05 | （空売り報告）野村證券 71,391株（0.28%）-0.48%義務消失 |
| 03/04 | 2,265 | 2,274 | 2,183 | 2,261 | -2.88% | 354,600 | 562億7877万 | +4.05% |
| 03/04 | （空売り報告）野村證券 191,191株（0.76%）+0.16% |
| 03/03 | 2,360 | 2,414 | 2,326 | 2,328 | -1.4% | 268,600 | 579億4648万 | +7.78% |
| 03/03 | （空売り報告）野村證券 151,691株（0.6%）再IN |
| 03/02 | 2,354 | 2,385 | 2,336 | 2,361 | -1.58% | 247,300 | 587億6788万 | +10.07% |
| 02/27 | （IR情報）15:30 2026年3月15日開催 ログミーFinance主催「個人投資家向けIRセミナー」登壇のお知らせ |
| 02/27 | 2,341 | 2,400 | 2,341 | 2,399 | +3.36% | 231,000 | 597億1374万 | +12.68% |
| 02/27 | （空売り報告）野村證券 41,091株（0.16%）-0.55%義務消失 |
| 02/26 | 2,322 | 2,351 | 2,309 | 2,321 | -0.81% | 175,400 | 577億7224万 | +10.05% |
| 02/26 | （空売り報告）野村證券 177,291株（0.71%）再IN |
| 02/25 | 2,372 | 2,390 | 2,326 | 2,340 | -1.64% | 141,300 | 582億4517万 | +11.85% |
| 02/25 | （空売り報告）野村證券 96,991株（0.38%）-0.3%義務消失 |
| 02/24 | 2,360 | 2,395 | 2,342 | 2,379 | -0.88% | 180,100 | 592億1592万 | +14.71% |
| 02/24 | （空売り報告）野村證券 170,091株（0.68%）再IN |
| 02/20 | （5%ルール）野村證券（7.38%）野村アセットマネジメント（1.67%） |
| 02/20 | 2,395 | 2,409 | 2,356 | 2,400 | +1.57% | 214,300 | 597億3864万 | +16.79% |
| 02/19 | （IR情報）16:30 非上場の親会社等の決算情報に関するお知らせ |
| 02/19 | 2,360 | 2,398 | 2,330 | 2,363 | -1.34% | 249,200 | 588億1766万 | +16.06% |
| 02/18 | 2,302 | 2,446 | 2,299 | 2,395 | +5.23% | 330,700 | 596億1418万 | +18.74% |
| 02/18 | （空売り報告）野村證券 115,191株（0.46%）-0.14%義務消失 |
| 02/17 | 2,296 | 2,296 | 2,251 | 2,276 | +0.09% | 183,200 | 566億5214万 | +13.91% |
| 02/17 | （空売り報告）野村證券 149,791株（0.6%）再IN |
| 02/16 | （IR情報）16:00 エルトロンボパグ錠 12.5mg「F」・エルトロンボパグ錠25mg「F」の製造販売承認取得および販売提携のお知らせ |
| 02/16 | 2,251 | 2,331 | 2,251 | 2,274 | +1.07% | 188,300 | 566億236万 | +14.67% |
| 02/13 | 2,247 | 2,343 | 2,229 | 2,250 | -0.53% | 358,700 | 560億497万 | +14.27% |
| 02/13 | （空売り報告）野村證券 88,391株（0.35%）-0.2%義務消失 |
| 02/12 | （5%ルール）野村證券（8.05%）野村アセットマネジメント（1.87%） |
| 02/12 | 2,135 | 2,310 | 2,135 | 2,262 | +4.97% | 478,700 | 563億366万 | +15.7% |
| 02/12 | （空売り報告）野村證券 137,491株（0.55%）再IN |
| 02/10 | （IR情報）15:30 緊急避妊薬「レソエル72」の製造販売承認取得および販売開始のお知らせ |
| 02/10 | 2,177 | 2,194 | 2,154 | 2,155 | -0.97% | 229,400 | 536億4032万 | +11.03% |
| 02/09 | 2,197 | 2,197 | 2,117 | 2,176 | +0.05% | 398,700 | 541億6303万 | +12.69% |
| 02/09 | （空売り報告）野村證券 101,491株（0.4%）-0.64%義務消失 |
| 02/06 | 2,324 | 2,324 | 2,153 | 2,175 | +13.05% | 1,225,300 | 541億3814万 | +13.34% |
| 02/06 | （空売り報告）野村證券 260,091株（1.04%）新規 |
| 02/05 | （IR情報）16:30 業績予想の修正に関するお知らせ |
| 02/05 | （IR情報）16:30 2026年9月期第1四半期有価証券評価損に関するお知らせ |
| 02/05 | （IR情報）16:30 2026年9月期第1四半期決算短信〔日本基準〕(連結) |
| 02/05 | 1,949 | 1,950 | 1,901 | 1,924 | +1.16% | 232,600 | 478億9047万 | +0.84% |
| 02/04 | 1,910 | 1,911 | 1,891 | 1,902 | -0.05% | 78,200 | 473億4287万 | -0.26% |
| 02/03 | （IR情報）16:30 婦人科領域におけるゲデオン・リヒター社との戦略的協業契約締結のお知らせ |
| 02/03 | 1,898 | 1,911 | 1,886 | 1,903 | +1.49% | 63,200 | 473億6776万 | -0.1% |
| 02/02 | 1,924 | 1,939 | 1,873 | 1,875 | -1.73% | 78,800 | 466億7081万 | -1.52% |
| 01/30 | 1,886 | 1,908 | 1,875 | 1,908 | +1.71% | 54,800 | 474億9221万 | +0.16% |
| 01/29 | 1,875 | 1,897 | 1,832 | 1,876 | -0.21% | 66,000 | 466億9570万 | -1.42% |
| 01/28 | 1,918 | 1,919 | 1,879 | 1,880 | -3.04% | 64,400 | 467億9526万 | -1.16% |
| 01/27 | 1,921 | 1,945 | 1,910 | 1,939 | +0.57% | 60,400 | 482億6384万 | +1.89% |
| 01/26 | 1,940 | 1,945 | 1,900 | 1,928 | -2.23% | 102,600 | 479億9004万 | +1.53% |
| 01/23 | 1,960 | 1,978 | 1,952 | 1,972 | +1.13% | 112,300 | 490億8524万 | +4.01% |
| 01/22 | 1,903 | 1,953 | 1,902 | 1,950 | +3.12% | 81,100 | 485億3764万 | +3.23% |
| 01/21 | 1,899 | 1,903 | 1,863 | 1,891 | -0.47% | 55,300 | 470億6907万 | +0.48% |
| 01/20 | （IR情報）17:00 ウステキヌマブのバイオ後続品（バイオシミラー） 新規規格に関する製造販売承認取得のお知らせ |
| 01/20 | 1,887 | 1,914 | 1,887 | 1,900 | +0.26% | 80,700 | 472億9309万 | +1.28% |
| 01/19 | 1,913 | 1,913 | 1,888 | 1,895 | -0.94% | 42,000 | 471億6863万 | +1.34% |
| 01/16 | 1,910 | 1,913 | 1,888 | 1,913 | +0.16% | 56,300 | 476億1667万 | +2.68% |
| 01/15 | 1,895 | 1,916 | 1,893 | 1,910 | +0.32% | 43,300 | 475億4200万 | +2.96% |
| 01/14 | 1,907 | 1,925 | 1,896 | 1,904 | -0.05% | 66,200 | 473億9265万 | +3.14% |
| 01/13 | 1,922 | 1,927 | 1,880 | 1,905 | -0.37% | 76,500 | 474億1754万 | +3.53% |
| 01/09 | 1,911 | 1,922 | 1,893 | 1,912 | +0.05% | 49,900 | 475億9178万 | +4.2% |
| 01/08 | 1,919 | 1,938 | 1,911 | 1,911 | +0.16% | 52,800 | 475億6689万 | +4.43% |
| 01/07 | 1,891 | 1,927 | 1,885 | 1,908 | +0.26% | 72,300 | 474億9221万 | +4.55% |
| 01/06 | 1,925 | 1,927 | 1,898 | 1,903 | -0.26% | 92,400 | 473億6776万 | +4.62% |
| 01/05 | 1,890 | 1,930 | 1,888 | 1,908 | +1.06% | 87,000 | 474億9221万 | +5.3% |
| 2025 |
| 12/30 | 1,878 | 1,915 | 1,878 | 1,888 | +0.27% | 95,400 | 469億9439万 | +4.54% |
| 12/29 | 1,902 | 1,911 | 1,869 | 1,883 | -0.89% | 97,800 | 468億6994万 | +4.61% |
| 12/26 | 1,876 | 1,909 | 1,876 | 1,900 | +1.33% | 83,800 | 472億9309万 | +5.85% |
| 12/25 | （IR情報）15:30 支配株主等に関する事項について |
| 12/25 | 1,869 | 1,893 | 1,867 | 1,875 | +1.13% | 88,500 | 466億7081万 | +4.98% |
| 12/24 | 1,886 | 1,893 | 1,847 | 1,854 | -2.47% | 75,400 | 461億4809万 | +4.27% |
| 12/23 | 1,863 | 1,905 | 1,863 | 1,901 | +1.71% | 108,500 | 473億1798万 | +7.34% |
| 12/22 | 1,890 | 1,890 | 1,849 | 1,869 | +0.59% | 96,900 | 465億2146万 | +6.13% |
| 12/19 | 1,904 | 1,904 | 1,841 | 1,858 | -2.62% | 174,200 | 462億4766万 | +5.93% |
| 12/18 | 1,852 | 1,911 | 1,837 | 1,908 | +3.86% | 157,400 | 474億9221万 | +9.28% |
| 12/17 | 1,861 | 1,869 | 1,827 | 1,837 | -0.54% | 106,800 | 457億2495万 | +5.82% |
| 12/16 | 1,802 | 1,847 | 1,794 | 1,847 | +2.5% | 105,200 | 459億7386万 | +7.07% |
| 12/15 | 1,762 | 1,805 | 1,762 | 1,802 | +1.81% | 63,800 | 448億5376万 | +5.07% |
| 12/12 | 1,743 | 1,780 | 1,743 | 1,770 | +2.37% | 76,800 | 440億5724万 | +3.75% |
| 12/11 | 1,756 | 1,765 | 1,721 | 1,729 | -1.54% | 65,700 | 430億3671万 | +1.83% |
| 12/10 | 1,726 | 1,767 | 1,726 | 1,756 | +1.74% | 58,000 | 437億877万 | +3.78% |
| 12/09 | 1,714 | 1,736 | 1,709 | 1,726 | +0.64% | 50,700 | 429億6203万 | +2.37% |
| 12/08 | 1,708 | 1,744 | 1,708 | 1,715 | +1.48% | 85,000 | 426億8823万 | +2.08% |
| 12/05 | 1,731 | 1,737 | 1,685 | 1,690 | -3.43% | 223,800 | 420億6595万 | +0.96% |
| 12/04 | 1,761 | 1,780 | 1,695 | 1,750 | -1.91% | 279,800 | 435億5942万 | +4.79% |
| 12/03 | 1,774 | 1,796 | 1,748 | 1,784 | -0.22% | 97,100 | 444億572万 | +7.21% |
| 12/02 | 1,757 | 1,804 | 1,753 | 1,788 | +1.07% | 91,200 | 445億528万 | +7.78% |
| 12/01 | 1,793 | 1,814 | 1,746 | 1,769 | 0% | 126,900 | 440億3235万 | +7.08% |
| 11/28 | 1,716 | 1,772 | 1,713 | 1,769 | +2.31% | 65,100 | 440億3235万 | +7.54% |
| 11/27 | 1,745 | 1,750 | 1,720 | 1,729 | -1.59% | 55,700 | 430億3671万 | +5.56% |
| 11/26 | 1,736 | 1,765 | 1,716 | 1,757 | +1.04% | 88,600 | 437億3366万 | +7.59% |
| 11/25 | 1,742 | 1,770 | 1,730 | 1,739 | -1.14% | 112,600 | 432億8562万 | +6.88% |
| 11/21 | （IR情報）15:30 タイOLICによるNextstellisの効能又は効果追加承認のお知らせ |
| 11/21 | 1,680 | 1,771 | 1,678 | 1,759 | +4.7% | 229,300 | 437億8344万 | +8.51% |
| 11/20 | 1,671 | 1,680 | 1,664 | 1,680 | +0.78% | 60,500 | 418億1704万 | +3.9% |
| 11/19 | 1,667 | 1,685 | 1,661 | 1,667 | 0% | 64,200 | 414億9346万 | +3.28% |
| 11/18 | 1,659 | 1,687 | 1,656 | 1,667 | -0.24% | 85,100 | 414億9346万 | +3.54% |
| 11/17 | 1,681 | 1,685 | 1,659 | 1,671 | -0.42% | 89,300 | 415億9302万 | +4.05% |
| 11/14 | 1,650 | 1,688 | 1,638 | 1,678 | +1.15% | 105,300 | 417億6726万 | +4.74% |
| 11/13 | 1,647 | 1,675 | 1,639 | 1,659 | +0.42% | 109,800 | 412億9433万 | +3.82% |
| 11/12 | 1,600 | 1,655 | 1,572 | 1,652 | +5.9% | 254,700 | 411億2009万 | +3.57% |
| 11/11 | （IR情報）16:30 2025年9月期決算短信〔日本基準〕(連結) |
| 11/11 | 1,604 | 1,604 | 1,550 | 1,560 | -2.62% | 110,500 | 388億3011万 | -1.95% |
| 11/10 | 1,588 | 1,602 | 1,576 | 1,602 | +1.71% | 96,200 | 398億7554万 | +0.69% |
| 11/07 | 1,590 | 1,598 | 1,562 | 1,575 | -0.63% | 36,100 | 392億348万 | -0.76% |
| 11/06 | 1,577 | 1,592 | 1,563 | 1,585 | +0.83% | 37,000 | 394億5239万 | +0.06% |
| 11/05 | 1,580 | 1,609 | 1,554 | 1,572 | -2.12% | 46,800 | 391億2880万 | -0.63% |
| 11/04 | （IR情報）15:30 バイオ後続品（バイオシミラー）ゴリムマブBSに関する契約締結のお知らせ |
| 11/04 | 1,580 | 1,622 | 1,578 | 1,606 | +1.77% | 95,700 | 399億7510万 | +1.52% |
| 10/31 | （IR情報）15:30 バイオ後続品（バイオシミラー）デノスマブBSに関する契約締結のお知らせ |
| 10/31 | 1,570 | 1,588 | 1,550 | 1,578 | +0.57% | 63,200 | 392億7815万 | -0.13% |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
